One Wealth Capital Management LLC Buys Shares of 622 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

One Wealth Capital Management LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 622 shares of the pharmaceutical company’s stock, valued at approximately $250,000.

Other hedge funds have also made changes to their positions in the company. Whalen Wealth Management Inc. acquired a new stake in Vertex Pharmaceuticals in the third quarter worth $662,000. Creative Planning increased its holdings in shares of Vertex Pharmaceuticals by 5.3% in the 2nd quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock worth $37,084,000 after acquiring an additional 3,998 shares during the period. Mizuho Securities USA LLC lifted its position in Vertex Pharmaceuticals by 289.0% in the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after purchasing an additional 57,497 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Vertex Pharmaceuticals during the 2nd quarter valued at about $21,008,000. Finally, Keynote Financial Services LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $498,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.6 %

Shares of VRTX stock traded up $6.29 during trading hours on Tuesday, reaching $408.78. 1,071,358 shares of the stock traded hands, compared to its average volume of 1,365,200. The business has a fifty day moving average price of $453.89 and a 200 day moving average price of $469.70. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $105.27 billion, a PE ratio of -205.42 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the prior year, the company earned $3.67 earnings per share. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several analyst reports. Canaccord Genuity Group boosted their price objective on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. Scotiabank boosted their price target on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a research report on Monday, December 23rd. Bank of America lowered their price target on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a report on Thursday, December 19th. Morgan Stanley upped their price objective on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, Barclays decreased their target price on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a research report on Friday, December 20th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $494.04.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.